SLC5A2 and type 2 diabetes mellitus: An [18F]-canagliflozin feasibility study to non-invasively quantify the tissue canagliflozin distribution and SGLT2 density in T2DM patients is currently ongoing (Netherlands Trial Register; NL7707).